Durability of Response to Axicabtagene Ciloleucel in Patients With Refractory DLBCL: Long-term Follow-up of Phase II ZUMA-1 Trial

June 1-5, 2018; Chicago, Illinois
Extended follow-up of this pivotal phase II trial suggests 3-month response to axi-cel may be prognostic of long-term remissions.
Format: Microsoft PowerPoint (.ppt)
File Size: 197 KB
Released: June 5, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Downloadable slideset on the latest clinical data on the management of endometrial cancer, from Clinical Care Options (CCO)

person default Linda R. Duska, MD, MPH Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on immunotherapy for HCC and BTCs

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 18, 2021

Short downloadable slideset from Clinical Care Options (CCO) on managing HR+/HER2- early breast cancer

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from CCO on the use of PI3K inhibitors in the treatment of follicular lymphoma.

John M. Burke, MD Nathan H. Fowler, MD Released: June 18, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue